Fig. 2From: Prior treatment status: impact on the efficacy and safety of teriflunomide in multiple sclerosisOverall adjusted ARR in patients treated with teriflunomide 14 mg (core and extension period). ARR annualized relapse rate, CI confidence interval, DMT disease-modifying therapyBack to article page